Adagrasib: a novel inhibitor for KRAS G12C -mutated non-small-cell lung cancer
Future Oncology · 2023
DOI: 10.2217/fon-2022-1106 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Future Oncology, 2023. Verfasst von Matthew Z Guo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 122 Literaturangaben. Gefördert von: Bristol-Myers Squibb and AstraZeneca.
Abstract (Originalsprache)
Adagrasib is a recently US FDA-approved novel KRASG12C targeted therapy with clinical efficacy in patients with advanced, pretreated KRASG12C-mutated non-small-cell lung cancer. KRYSTAL-I reported an objective response rate of 42.9% with median duration of response of 8.5 months. Treatment-related adverse events were primarily gastrointestinal and occurred in 97.4% of patients, with grade 3+ treatment-related adverse events occurring in 44.8% of patients. This review details the preclinical and clinical data for adagrasib in the treatment of non-small-cell lung cancer. We also outline practical clinical administration guidelines for this novel therapy, including management of toxicities. Finally, we discuss the implications of resistance mechanisms, summarize other KRASG12C inhibitors currently in development and outline future directions for adagrasib-based combination therapies. Adagrasib is a new oral (taken by mouth) treatment option for patients with non-small-cell lung cancer (NSCLC) with KRASG12C mutations. KRAS is a gene that regulates signaling pathways, which are responsible for cell growth and division. A mutation in KRAS can cause cells to multiply and cause cancer. Clinical trials have shown that adagrasib causes cancer reduction or resolution in 42.9% of people with NSCLC with KRASG12C mutations who receive the drug. Side effects of adagrasib are primarily gastrointestinal (nausea, vomiting, diarrhea). This review outlines guidelines for the management of side effects. New studies are looking at how adagrasib can be safely combined with other therapies to better treat NSCLC with KRASG12C mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Johns Hopkins School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
- Virginia Cancer Specialists Research Institute, Fairfax, VA, USA.
- US Oncology Research, The Woodlands, TX, USA.
- NEXT Oncology, San Antonio, TX, USA.
ORCID-Profile: Matthew Z Guo
Förderung
- Bristol-Myers Squibb and AstraZeneca
Zitieren
APA
Guo, M. Z., Marrone, K. A., Spira, A., & Rosner, S. (2023). Adagrasib: a novel inhibitor for KRAS G12C -mutated non-small-cell lung cancer. Future Oncology. https://doi.org/10.2217/fon-2022-1106
Vancouver
Guo MZ, Marrone KA, Spira A, Rosner S. Adagrasib: a novel inhibitor for KRAS G12C -mutated non-small-cell lung cancer. Future Oncology. 2023. doi:10.2217/fon-2022-1106
BibTeX
@article{Guo2023,
author = {Guo, Matthew Z and Marrone, Kristen A and Spira, Alexander and Rosner, Samuel},
title = {Adagrasib: a novel inhibitor for KRAS G12C -mutated non-small-cell lung cancer},
journal = {Future Oncology},
year = {2023},
doi = {10.2217/fon-2022-1106}
}
EUVIMED